Clinical trial · Interventional
Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells
Treatment of Metastatic Tumors of the Urogenital Area (Bladder Cancer, Renal Cancel) With Cytokine-induced Killer Cells
NCT05108077CI-TRIAL-00055985unknownPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Renal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cytokine-induced killer cells | Biological | — | UNRESOLVED |
| Standard treatment according to the Clinical protocols | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cytokine-induced killer cells
- description
- Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
- interventionNames
- Biological: cytokine-induced killer cells
- Other: Standard treatment according to the Clinical protocols
- type
- ACTIVE_COMPARATOR
- label
- Control
- description
- Patients with metastatic tumors of the urogenital area receiving standard treatment
- interventionNames
- Other: Standard treatment according to the Clinical protocols
Primary outcomes (5)
- measure
- The relapse-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of pTa metastatic tumors of the urogenital area; * Patient who require repetitive transurethral resection; * Expression of muc-1/wt-1 by the tumor; * EGOC 0-3; Exclusion Criteria: * any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis B/C, tuberculosis, HIV
References
Publications (0)
Data not yet available
No reference posted for this study.